Huntingtin is required for neurogenesis and is not impaired by the Huntington's disease CAG expansion - Nature Genetics
- ️MacDonald, Marcy E.
- ️Mon Dec 01 1997
Martin, J.B. & Gusella, J.F. Huntington's disease: pathogenesis and management. N. Engl. J. Med. 315, 1267–1276 (1986).
Vonsattel, J.P. et al. Neuropathological classification of Huntington's disease. J. Neuropathol. Exp. Neuml. 44, 559–577 (1985).
A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. Cell. 72, 971–983 (1993).
McNeil, S.M. et al. Reduced penetrance of the Huntington's disease mutation. Hum. Mol. Genet. 6, 775–779 (1997).
Rubinsztein, D.C. et al. Phenotypic characterization of individuals with 30–40 CAG repeats in the Huntington disease (HD) gene reveals HD cases with 36 repeats and apparently normal elderly individuals with 36–39 repeats. Am. J. Hum. Genet. 59, 16–22 (1996).
Gusella, J.F., Persichetti, F. & MacDonald, M.E. The genetic defect causing Huntington's disease: repeated in other contexts. Mol. Med. 3, 238–246 (1997).
Ide, K. et al. Abnormal gene product identified in Huntington's disease lymphocytes and brain. Biochem. Biophys. Res. Commun. 209, 1119–1125 (1995).
Trottier, Y. et al. Cellular localization of the Huntington's disease protein and discrimination of the normal and mutated form. Nature Genet. 10, 104–110 (1995).
Jou, Y.S. & Myers, R.M. Evidence from antibody studies that the CAG repeat in the Huntington disease gene is expressed in the protein. Hum. Mol. Genet. 4, 465–469 (1995).
Sharp, A.H. et al. Widespread expression of Huntington's disease gene (IT15) protein product. Neuron. 14, 1065–1074 (1995).
DiFiglia, M. et al. Huntingtin is a cytoplasmic protein associated with vesicles in human and rat brain neurons. Neuron. 14, 1075–1081 (1995).
Gutekunst, C.-A. et al. Identification and localization of huntingtin in brain and human lymphoblastoid cell lines with anti-fusion protein antibodies. Proc. Natl. Acad. Sci. USA. 92, 8710–8714 (1995).
Persichetti, F. et al. Normal and expanded Huntington's disease alleles produce distinguishable proteins due to translation across the CAG repeat. Mol. Med. 1, 374–383 (1995).
Trottier, Y. et al. Polyglutamine expansion as a pathological epitope in Huntington's disease and four dominant cerebellar ataxias. Nature. 378, 403–406 (1995).
Persichetti, F. et al. Huntington's disease CAG trinucleotide repeats in neuropathologically confirmed post-mortem brains. Neurobiol. Dis. 1, 159–166 (1995).
Li, X.J. et al. A huntingtin-associated protein enriched in brain with implications for pathology. Nature. 378, 398–402 (1995).
Bao, J. et al. Expansion of polyglutamine repeat in huntingtin leads to abnormal protein interactions involving calmodulin. Proc. Natl. Acad. Sci. USA. 93, 5037–5042 (1996).
Burke, J.R. et al. Huntingtin and DRPLA proteins selectively interact with the enzyme GAPDH. Nature Med. 2, 347–350 (1996).
Kalchman, M.A. et al. HIP1, a human homologue of S cerevisiae Sla2p, interacts with membrane-associated huntingtin in the brain. Nature Genet. 16, 44–53 (1997).
Wanker, E.E. et al. HIP-I: a huntingtin interacting protein isolated by the yeast two-hybrid system. Hum. Mol. Genet. 6, 487–495 (1997).
Ambrose, C.M. et al. Structure and expression of the Huntington's disease gene: evidence against simple inactivation due to an expanded CAG repeat. Somatic Cell Mol. Genet. 20, 27–38 (1994).
Duyao, M.P. et al. Homozygous inactivation of the mouse Hdh gene does not produce a Huntington's disease-like phenotype. Science. 269, 407–410 (1995).
Zeitlin, S. et al. Increased apoptosis and early embryonic lethality in mice nullizygous for the Huntington's disease gene homologue. Nature Genet. 11, 155–162 (1995).
Myers, R.H. et al. Homozygote for Huntington's disease. Am. J. Hum. Genet. 45, 615–618 (1989).
Wexler, N.S. et al. Homozygotes for Huntington's disease. Nature. 326, 194–197 (1987).
Nasir, J. et al. Targeted disruption of the Huntington's disease gene results in embryonic lethality and behavioral and morphological changes in heterozygotes. Cell. 81, 811–823 (1995).
MacDonald, M.E. & Gusella, J.F. Huntington's disease: translating a CAG repeat into a pathogenic mechanism. Curr. Opin. Neurobiol. 6, 638–650 (1996).
Barnes, G.T. et al. Mouse Huntington's disease gene homolog (Hdh). Somat. Cell Mol. Genet. 20, 87–97 (1994).
Lin, B. et al. Sequence of the murine Huntington disease gene: evidence for conservation, alternate splicing and polymorphism in a triplet (CCG) repeat [published erratum appears in Hum. Mol. Genet. 3, 530 (1994)]. Hum. Mol. Genet. 3, 85–92 (1994).
MacDonald, M.E. et al. Targeted inactivation of the mouse Huntington disease homologue Hdh . Cold Spring Harbor Symp Quant. Biol. 61, 627–638 (1996).
Lin, B. et al. Structural analysis of the 5′ region of mouse and human Huntington disease genes reveals conservation of putative promoter region and di- and trinucleotide polymorphisms. Genomics. 25, 707–715 (1995).
Stumpo, D.J. et al. MARCKS deficiency in mice leads to abnormal brain development and perinatal death. Proc. Natl. Acad. Sci. USA. 92, 944–948 (1995).
Wu, M. et al. Neural tube defects and abnormal brain development in F52-deficient mice. Proc. Natl. Acad. Sci. USA. 93, 2110–2115 (1996).
Hui, C.-C. & Joyner,, A.L A mouse model of Greig cephalo-polysyndactyly syndrome: the extra-toesJ mutation contains an intragenic deletion of the GH3 gene. Nature Genet. 3, 241–246 (1993).
Shah, V. et al. A subset of p53-deficient embryos exhibit exencephaly. Nature Genet. 10, 175–180 (1995).
Kuida, K. et al. Decreased apoptosis in the brain and premature lethality in CPP32-deficient mice. Nature. 384, 368–372 (1996).
Gusella, J.F., Persichetti, F. & MacDonald, M.E. The genetic defect causing Huntington's disease: repeated in other contexts. Mol. Med. 3, 238–246 (1997).
Bingham, P.M. et al. Stability of an expanded trinucleotide repeat in the androgen receptor gene in transgenic mice [published erratum appears in. Nature Genet. 9, 191–196 (1995).
Goldberg, Y.P. et al. Absence of disease phenotype and intergenerational stability of the CAG repeat in transgenic mice expressing the human Huntington disease transcript. Hum. Mol. Genet. 5, 177–185 (1996).
Ikeda, H. et al. Expanded polyglutamine in the Machado-Joseph disease protein induces cell death in vitro and in vivo . Nature Genet. 13, 196–202 (1996).
Burright, E.N. et al. SCA1 transgenic mice: a model for neurodegeneration caused by an expanded CAG trinucleotide repeat. Cell. 82, 937–948 (1995).
Mangiarini, L.E. et al. Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice. Cell. 87, 493–506 (1996).
Hanks, M. et al. Rescue of the En-1 mutant phenotype by replacement of En-1 with En-2 . Science. 269, 679–682 (1995).
Warner, J.P., Barren, L.H. & Brock, D.J. A new polymerase chain reaction (PCR) assay for the trinucleotide repeat that is unstable and expanded on Huntington's disease chromosomes. Mol. Cell. Probes. 7, 235–239 (1993).
Nagy, A. et al. Derivation of completely cell culture–derived mice from early-passage embryonic stem cells. Proc Natl. Acad. Sci. USA. 90, 8424–8428 (1993).
Wurst, W. & Joyner, A.L. Production of targeted embryonic stem cell clones in Gene Targeting: A Practical Approach (ed. A.L. Joyner) 33–62 (Oxford University Press, Oxford, UK, 1993).
Nagy, A. & Rossant, J. Production of completely ES cell-derived fetuses. in Gene Targeting: A Practical Approach (ed. A.L. Joyner) 147–180 (Oxford University Press, Oxford, UK, 1993).
Miller, M.W. & Nowakowski, R.S. Use of bromodeoxyuridine-immunohistochemistry to examine the proliferation, migration and time of origin of cells in the central nervous system. Brain Res. 457, 44–52 (1988).